Indoco receives ANDA approval for Glimepiride tablets from USFDA . April 18, 2013
	Suresh G. Kare to receive the 'Udyog Shree Jeevan Gaurav Sanman' on March 29, 2013 at the hands of Hon'ble Chief Minister of Goa, Mr. Manohar Parrikar March 22, 2013
	Indoco's Chairman Mr. Suresh G. Kare to receive the 'Udyog Shree Lifetime Achievement Award' February 11, 2013
	Indoco Remedies Limited bags award for 'Innovation in Quality’ at CPhI India Pharma Awards 2012 November 27, 2012
	Indoco CND, a new division for care in Cardiology and Diabetology April 4, 2012
	Mr. Sundeep V. Bambolkar honoured for the second time at the ‘CFO 100 Awards’ 2012 March 29, 2012
	Third Generation takes over the Management reins at Indoco... February 14, 2012
	Change of Company Secretary & Compliance Officer February 8, 2012
	Indoco enters into a marketing and sales alliance with DSM, a € 9 billion Company January 31, 2012
	Indoco Remedies - Fixes Book Closure for Dividend & AGM - BSE ANNOUNCEMENT  June 24, 2011
	Indoco Remedies Board recommends Dividend May 28, 2011
	Indoco Remedies - Change in Directorship October 20, 2010
	Indoco Launches ‘Xtend’- An Extra Urban Division  July 14, 2010
	Indoco Remedies - Fixes Book Closure for Dividend & AGM - BSE ANNOUNCEMENT  June 22, 2010
	Board recommends Dividend -   May 31, 2010
	Board to consider the Audited Accounts for FY 2009-10 -   May 21, 2010
	INDOCO teams up with ASPEN for emerging markets  March 29, 2010
	Indoco Remedies Licenses Out Technology to Watson Pharmaceuticals Inc. USA  February 1, 2010
	Indoco Remedies Board recommends Final Dividend  July 30, 2009
	Indoco Board to meet to consider unaudited financial results for Q1FY10 and audited accounts & declaration of final dividend, if any, for the FY08-09 -   July 17, 2009
	Result of Postal Ballot - January 9, 2009
	Indoco Remedies - Notice of Postal Ballot - BSE ANNOUNCEMENT  December 2, 2008
	Indoco Remedies fixes Record Date for interim dividend - BSE ANNOUNCEMENT  November 28, 2008
	Indoco Remedies Board declares interim dividend - BSE ANNOUNCEMENT  November 26, 2008
	Indoco Remedies Board to consider interim dividend - BSE ANNOUNCEMENT  November 18, 2008
	Indoco Remedies Board recommends dividend - BSE ANNOUNCEMENT  September 5, 2008
	Indoco Remedies - Board Meeting adjourned - BSE ANNOUNCEMENT  September 4, 2008
	Indoco Remedies Board to consider dividend - BSE ANNOUNCEMENT  August 20, 2008
	Indoco Changes its Financial Year Ending to 31st March  April 24, 2008
	Outcome of Board Meeting - BSE ANNOUNCEMENT  February 25, 2008
	Indoco Remedies Ltd has decided to take up 100% equity stake in Shree Herbal Technologies Ltd (BSE ANNOUNCEMENT)  January 29, 2008
	Indoco Remedies enters into a Joint Venture partnership with US based company to launch Ophthalmics in US  October 18, 2007
	Indoco Remedies geared up for Brazil  July 4, 2007
	Change of Company Secretary & Compliance Officer February 8, 2012 Indoco Remedies Ltd has informed BSE that Mr. Sunil Joshi has been appointed as Company Secretary & Compliance Officer of the Company w.e.f. February 08, 2012, in place of Mr. Jagdish B. Salian who would retire as Company Secretary & Compliance Officer from February 07, 2012. ^Top
	Indoco enters into a marketing and sales alliance with DSM, a € 9 billion Company January 31, 2012 Indoco announced the signing of an agreement with DSM for commercial cooperation for eight Active Pharmaceutical Ingredients (APIs). Indoco and DSM have agreed to form a strategic alliance, wherein DSM shall be marketing and selling the APIs manufactured by INDOCO. In line with Indoco's strategy, this agreement paves the way for Indoco to expand its presence in markets across the globe for APIs and enables Indoco to leverage its product development and cGMP (current Good Manufacturing Practices) compliant manufacturing capabilities. Mr. Suresh G. Kare, Chairman & Managing Director, Indoco Remedies Ltd., commented, “Today in the era of alliances and partnerships, organizations are coming together to penetrate and capture a larger share of the potential opportunities in the market place. Indoco is active in forging such a lliances and this one with DSM is a step in that direction. This alliance offers a great opportunity to expand our global presence with a well established partner like DSM." Founded in 1947, Indoco Remedies Limited is one of the leading manufacturers of APIs and Finished Dosages in India for various therapeutic classes. USDMFs (US Drug Master Files), CoS (Certificate of Suitability) applications and DMFs ( Drug Master Files) have been filed by Indoco for some APIs and the Company has been seeking to expand supplies to major markets worldwide, including European and US generic and branded pharmaceutical companies. Alexander Wessels, President and Chief Executive Officer, DSM Pharmaceutical Products (DPP) stated, “This is a step in our announced strategy to accelerate growth via partnerships and expansion in Asia to build a product portfolio alongside our custom manufacturing operations, supplying access to high demand treatments. It allows DPP to build a competence base in India” The Indoco alliance is anchored in DSM's API business, DSM Pharma Chemicals, headquartered in Austria. DSM Pharmaceutical Products is a Business Group of Royal DSM N.V. and is a global science-based company active in health, nutrition and materials. DSM’s 22,000 employees deliver annual net sales of about € 9 billion. The company is listed on NYSE Euronext. Indoco preferred DSM for this strategic alliance based on DSM’s longstanding pharmaceutical customer contacts and presence in markets worldwide combined with their deep commitment to quality. About DSM ^Top
	Indoco Remedies - Fixes Book Closure for Dividend & AGM - BSE ANNOUNCEMENT June 24, 2011 Indoco Remedies Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 21, 2011 to July 28, 2011 (both days inclusive) for the purpose of Payment of Dividend & Annual General Meeting (AGM) of the Company to be held on July 28, 2011.  ^Top
	Indoco Remedies Board recommends Dividend May 28, 2011 At the meeting held on May 28, 2011, the Board has decided to recommend a dividend of Rs. 8/- per equity share of Rs. 10/- each of the Company (80%) for the year ended March 31, 2011. The dividend when approved at the AGM will be paid on or after August 08, 2011 to those shareholders whose names appear on the register of members as on the record date. ^Top
	Indoco Remedies - Change in Directorship October 20, 2010 - Resignation of Mr. FX Coutinho as Executive Director - Marketing with effect from 20th October, 2010. - Ms. Aditi Kare Panandikar, to take over charge of Marketing functions from Mr. Coutinho in addition to HR & Business Development as per Board's request. ^Top
	Indoco Remedies - Fixes Book Closure for Dividend & AGM - BSE ANNOUNCEMENT June 22, 2010 Indoco Remedies Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 15, 2010 to July 22, 2010 (both days inclusive) for the purpose of Payment of Dividend for the financial year 2009-10.  ^Top
	Board recommends Dividend May 31, 2010 The Board of Directors of the Company at its meeting held on May 31, 2010, inter alia, recommended payment of divided of Rs. 7.00 per equity share i.e. 70% for financial year 2009-10 subject to the approval of members in the ensuing Annual General Meeting. ^Top
	Board to consider the Audited Accounts for FY 2009-10 May 21, 2010 Indoco Remedies Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 31, 2010, inter alia, to consider, the following businesses: 1. To consider the audited financial results for the year ended March 31, 2010 and 2. To consider recommendation of dividend, if any, for the financial year 2009-10. ^Top
	Indoco Remedies Licenses Out Technology to Watson Pharmaceuticals Inc. USA February 1, 2010 Indoco Remedies Ltd., a Mumbai-based pharmaceutical company, announces the finalization of a generic product development alliance with Watson Pharmaceuticals, Inc. to develop and manufacture a number of sterile products for the United States market. Under the terms of agreement, Indoco will develop, manufacture and supply a number of products to Watson for the US market. The current US market size of these products is US$ 679 million. Commenting on the performance, Mr. Suresh G. Kare, Chairman & Managing Director said, “This is a milestone deal for Indoco as out-licensing technology to a company of Watson’s scale is a remarkable achievement. Watson Pharmaceuticals deal has the potential to propel Indoco’s international business revenues to greater heights.” Indoco is fully integrated to provide API manufacturing, formulation development and manufacturing of the generic formulations for the selected products. Watson will prepare and file the Abbreviated New Drug Applications (ANDAs) for US FDA approval and will have rights to market, sell and distribute these products in the US pharmaceutical market. For competitive reasons, details on the products to be developed have not been disclosed. As mutually agreed upon by both Watson and Indoco, development costs, including bio-study / clinical trials costs, legal fees and net profits from the sale of these products will be shared by Watson and Indoco in the agreed proportion. Indoco will work together with Watson to explore the option of adding new products and territories to this initial arrangement. ^Top
	Indoco Remedies Board recommends Final Dividend July 30, 2009 Indoco Remedies Limited has informed the NSE and BSE that the Board of Directors of the Company at its meeting held on July 30, 2009, recommended a final dividend of Rs 2.00 per equity share (20%). The Company had earlier paid an Interim Dividend of Rs 3.25 per equity share (32.5%) during the year. The final dividend if approved at the AGM, the dividend for the financial year 2008-09 would work out to Rs 5.25 per equity share (52.5%). ^Top
	Indoco Board to meet to consider unaudited financial results for Q1FY10 and audited accounts & declaration of final dividend, if any, for the FY08-09 July 17, 2009 Indoco Remedies Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on July 30, 2009, inter alia, to consider the following businesses: 1. To consider and take on record the unaudited financial results of the Company for the quarter ended June 30, 2009. 2. To consider the audited financial results for the year ended March 31, 2009 and 3. To consider recommendation of final dividend, if any, for the financial year 2008-2009. 2009. ^Top
	Indoco Remedies - Notice of Postal Ballot - BSE ANNOUNCEMENT December 2, 2008 Indoco Remedies Ltd has informed BSE that members of the Company will consider the following resolutions by way of Postal Ballot : 1. Authority to transfer, sell and / or dispose of Company's undertaking at 18A Mahal Estate, Andheri, Mumbai. 2. Alteration of the object clause of Memorandum of Association of the Company and commencement of new business. Click here for more details ^Top
	Indoco Remedies fixes Record Date for interim dividend - BSE ANNOUNCEMENT November 28, 2008 Indoco Remedies Ltd has informed BSE that December 12, 2008 has been fixed as the Record Date for the purpose of payment of interim dividend.  ^Top
	Indoco Remedies Board declares interim dividend - BSE ANNOUNCEMENT November 26, 2008 Indoco Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on November 26, 2008, has decided to declare an interim dividend of Rs 3.25 per share (32.5%) for the financial year 2008-09.  ^Top
	Indoco Remedies Board to consider interim dividend - BSE ANNOUNCEMENT November 18, 2008 Indoco Remedies Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on November 26, 2008, for the purpose of considering a proposal for declaration of an interim dividend for the financial year 2008-2009.  ^Top
	Indoco Remedies Board recommends dividend - BSE ANNOUNCEMENT September 5, 2008 Indoco Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on September 05, 2008, inter alia, has confirmed the proposal for recommendation of a dividend of Rs 5.00 per share (50%) for the financial year ended March 31, 2008 (9 months).  ^Top
	Indoco Remedies - Board Meeting adjourned - BSE ANNOUNCEMENT September 4, 2008 Indoco Remedies Ltd has informed BSE that the Board Meeting of the Company convened on September 02, 2008 for consideration of audited financial results and declaration of divided, if any, has been adjourned, and the adjourned meeting will be held on September 05, 2008 for consideration of audited financial results and declaration of dividend, if any, will be considered for the financial year ended March 31, 2008.  ^Top
	Indoco Remedies Board to consider dividend - BSE ANNOUNCEMENT August 20, 2008 Indoco Remedies Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on September 02, 2008, inter alia, for considering the audited financial results for the financial year ended on March 31, 2008, and recommendation of dividend, if any, for the financial year 2007- 2008.  ^Top
	Indoco Changes its Financial Year Ending to 31st March April 24, 2008 Indoco Remedies Limited will have March financial year ending from this fiscal. The Board of Directors of Indoco Remedies Limited, which hitherto had a financial year that ended in June, has decided to change its year ending to March with immediate effect. Resultantly, its FY0708 will reflect the performance of a nine-month period ended March 31st, 2008. Mr. Suresh G. Kare, Chairman and Managing Director, Indoco Remedies Limited said, “This corporate action will align our financial year with that commonly followed in the industry facilitating uniform, timely and efficient financial reporting.” The results for the nine (9) month period will be announced by Indoco Remedies Limited on April 30, 2008.  ^Top
	Outcome of Board Meeting - BSE ANNOUNCEMENT February 25, 2008 Indoco Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on February 23, 2008, has approved the following: 1. Change of Company's financial year ending from June 30th to March 31st. Consequently, the financial year of the Company for 2007-08 will be for a 9 months period from July 01, 2007 to March 31, 2008. 2. A Scheme of Amalgamation for a proposal to amalgamate Company's 100% subsidiary, Shree Herbal Technologies Ltd., with the Company. Further the Company has informed that, the Board of Directors of the Company has accepted the resignation of Mr. Atul S Rajadhyaksha as Director w.e.f. February 23, 2008 and has appointed Mr. Sharad P Upasani as the Director w.e.f. February 23, 2008 in the vacancy caused by the resignation of Mr. Atul S Rajadhyaksha.  ^Top
	Indoco Remedies Ltd has decided to take up 100% equity stake in Shree Herbal Technologies Ltd (BSE ANNOUNCEMENT) January 29, 2008 Indoco Remedies Ltd has informed BSE that the Board of Directors of the Company at its meeting held on January 29, 2008, has decided to take up 100% equity stake in Shree Herbal Technologies Ltd (SHTL) for a consideration of Rs 251.00 lacs. The investment will make SHTL a wholly owned subsidiary of the Company. SHTL is an unlisted Company with registered office at Delhi. It was incorporated in 2005 and is yet to commence manufacturing operations. The Company will leverage its manufacturing capacity from the investment.  ^Top
	Indoco Remedies enters into a Joint Venture partnership with US based company to launch Ophthalmics in US October 18, 2007 Mumbai, October 18, 2007: Indoco Remedies Limited and Amneal Pharmaceuticals, a New Jersey-based developer, manufacturer and distributor of generic pharmaceuticals announce the finalization of a joint venture partnership to develop, manufacture, market and distribute several products for the United States market. The initial product pipeline will include at least ten ophthalmic products, several of which have already progressed substantially through the development process. Under the terms of this agreement, the expertise of each company will be leveraged to create a highly efficient and effective product flow, from API manufacturing through regulatory approval and distribution that will bring at least ten high-quality generic drugs to the US market over the next five years. The product selection committee, made up of three members from each company, chose the first group of products to build a balanced offering in the ophthalmic category, providing potential customers a single source for the most important molecules of the category. Indoco’s responsibilities within the joint venture are, API manufacturing for the majority of these products, formulation development, analytical method development, production of bioequivalence batches, data reporting and ultimately manufacturing of the approved generic drugs for export to U.S. Amneal’s role in the partnership is to prepare and file the ANDAs for US FDA approval using the emerging eCTD/QBR/QOS process, maintaining all required FDA and regulatory agency documentation both prior to and following approval as well as to exclusively sell, market and distribute these products throughout the US pharmaceutical market across all segments. With balanced input from both Amneal and Indoco, funding for developing all these products, including bio-study costs, legal fees and other development expenses, will be equally shared. Likewise, the financial benefit from the sale of these products will be shared. For additional development after this initial group of products, Indoco and Amneal have already begun to identify several more products to pursue, in the ophthalmic category as well as other therapeutic categories and dosage forms. The two companies fully expect this agreement to expand significantly in the near term and for it to last for many years. In Amneal, Indoco now has a young and growing US generic company as a partner to market their ophthalmic products in USA. This partnership will help Indoco to speedily introduce their products in the U.S. market and to explore other areas of growth opportunities in the largest generic market of the world.  ^Top
	Indoco Remedies geared up for Brazil July 4, 2007 Indoco Remedies Solid Dosage facility at Goa secures ANVISA, Brazil approval. Mumbai, July 4, 2007: Indoco Remedies Ltd today announced that its solid dosage facility at Goa, Plant I has received approval from Brazilian food and drug agency, ANVISA, marking the beginning of company’s foray into one of the largest pharmaceutical market in the world. This approval paves way for contract manufacturing opportunities for Indoco in Brazil. Ms. Aditi Kare Panandikar, Director Business development said, "As a part of companies growth strategy & to move up the value chain, Indoco Remedies intends to enter newer, semi-regulated and regulated markets worldwide after getting approvals from the respective regulatory authorities”.  In addition, Indoco Remedies is working towards obtaining MCC approvals, for their Solid dosage as well as Sterile Plants. Out of Company’s two manufacturing facilities at Goa, Plant I is approved by MHRA-UK, for Tablets, Cream & Capsules and by Darmstadt Germany for Solid Dosages. Plant II is a state-of-the-art sterile facility for Ophthalmics and Injectables approved by USFDA.  ^Top